Johnson & Johnson reported higher fourth-quarter revenue and profit as strong sales of cancer and autoimmune drugs offset a sharp decline from the loss of patent protection on Stelara, according to The Wall Street Journal. Net earnings rose 20.8% to $5.12 billion, or $2.10 per share, while adjusted earnings of $2.46 per share matched estimates. Stelara sales fell nearly 48%, but growth in Darzalex and Tremfya helped stabilize results. J&J forecast 2026 adjusted earnings of $11.53 per share on $100.5 billion in sales, above analyst expectations, and projected more than 6% sales growth despite higher tariffs and drug price cuts tied to a deal with the Trump administration.
